Collegium diversifies with $604M BDSI buyout, adding pain & migraine meds
Collegium Pharmaceutical’s acquisition of BioDelivery Sciences International brings a pain drug that’s administered in a different way than its current lineup of medicines. The deal also gives Collegium a way to break into the neurology market.